CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer

被引：0
|
作者：
Lazaratos, Anna-Maria [1 ]
Petrecca, Kevin [2 ]
Guiot, Marie-Christine [2 ]
Dankner, Matthew [1 ]
Jerzak, Katarzyna J. [3 ]
机构：
[1] McGill Univ, Rosalind & Morris Goodman Canc Res Inst, Montreal, PQ H3A 1A3, Canada
[2] McGill Univ, Montreal Neurol Inst Hosp, Montreal, PQ H3A 1A3, Canada
[3] Univ Toronto, Sunnybrook Odette Canc Ctr, Div Med Oncol, Toronto, ON, Canada
来源：
LANCET ONCOLOGY | 2024年 / 25卷 / 07期
关键词：
BRAIN METASTASES;
D O I：
10.1016/S1470-2045(24)00261-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e282 / e282
页数：1
相关论文
共 50 条
  • [41] Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? - Reply
    Langer, CJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1326 - 1327
  • [42] HER2: defining a Neu target in non-small-cell lung cancer
    Ekman, S.
    ANNALS OF ONCOLOGY, 2019, 30 (03) : 353 - 355
  • [43] Non-small cell Lung Cancer: Trastuzumab and Deruxtecan Compination has an anti-cancer effect
    Metzger, Leandra
    PNEUMOLOGIE, 2021, 75 (11): : 835 - 835
  • [44] A randomized phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer.
    Yamaguchi, Kensei
    Bang, Yung-Jue
    Sakai, Daisuke
    Yasui, Hisateru
    Kawaguchi, Yoshinori
    Sugihara, Masahiro
    Saito, Kaku
    Dalal, Rita
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Phase 2 Study of Disitamab Vedotin in Patients with HER2-Expressing Non-Small Cell Lung Cancer (DV-005; Trial in Progress)
    Riess, J.
    Pothuri, B.
    Gabrail, N.
    Castonguay, V.
    Sanborn, R. E.
    Kalmadi, S.
    Li, X.
    Yang, M.
    Dumbrava, E. E.
    Liu, J. F.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S243 - S243
  • [46] The combination of trastuzumab and HER2-directed peptide vaccines is safe in HER2-expressing breast cancer patients
    Hale, D. F.
    Vreeland, T. J.
    Perez, S. A.
    Berry, J. S.
    Ardavanis, A.
    Trappey, A. F.
    Tzonis, P.
    Sears, A. K.
    Clifton, G. T.
    Shumway, N. M.
    Papamichail, M.
    Ponniah, S.
    Peoples, G. E.
    Mittendorf, E. A.
    CANCER RESEARCH, 2012, 72
  • [47] Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer
    Cai, Qi
    You, Shuhui
    Huang, Jinglong
    Gong, Caifeng
    Zhang, Wen
    Zhou, Aiping
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [48] Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
    Azar, Ibrahim
    Alkassis, Samer
    Fukui, Jami
    Alsawah, Fares
    Fedak, Kalub
    Al Hallak, Mohammed Najeeb
    Sukari, Ammar
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 103 - 114
  • [49] HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: a case report
    Guren, Ali Kaan
    Kocaaslan, Erkam
    Agyol, Yesim
    Majidova, Nargiz
    Sever, Nadiye
    Erel, Pinar
    Celebi, Abdussamet
    Arikan, Rukiye
    Isik, Selver
    Sari, Murat
    Bayoglu, Ibrahim Vedat
    Koestek, Osman
    ANTI-CANCER DRUGS, 2024, 35 (08) : 769 - 773
  • [50] Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02
    Oaknin, Ana
    Lee, Jung-Yun
    Makker, Vicky
    Oh, Do-Youn
    Banerjee, Susana
    Gonzalez-Martin, Antonio
    Jung, Kyung Hae
    Lugowska, Iwona
    Manso, Luis
    Manzano, Aranzazu
    Melichar, Bohuslav
    Siena, Salvatore
    Stroyakovskiy, Daniil
    Fielding, Anitra
    Puvvada, Soham
    Smith, Ann
    Meric-Bernstam, Funda
    ADVANCES IN THERAPY, 2024, 41 (11) : 4125 - 4139
12345